

Express Mail No.:EL 477 035 090 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Bhagwat et al.

Application No.: 09/910,950 Group Art Unit: 1614

Filed: July 23, 2001 Examiner: To Be Assigned

For: INDAZOLE DERIVATIVES AS Attorney Docket No.: 10624-047-999

JNK INHIBITORS AND

COMPOSITIONS AND METHODS

RELATED THERETO

REQUEST FOR CORRECTION OF FILING RECEIPT

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231

Sir:

Enclosed is the original corrected filing receipt and one copy thereof for the present application.

Please note the errors where highlighted on the copy of the filing receipt:

Applicant(s) are incorrect. The correct applicants are:

Shripad S. Bhagwat, San Diego, CA; Yoshitaka Satoh, San Diego, CA; Steven T. Sakata, San Diego, CA; Chris A. Buhr, Redwood City, CA; Ronald Albers, La Jolla, CA; John Sapienza, Chula Vista, CA; Veronique Plantevan; San Diego, CA; Qi Chao, San Diego, CA; Kiran Sahasrabudhe, San Diego, CA; and Rachel Ferri, San Diego, CA.

Filed concurrently herewith is a Declaration for Non-Provisional Patent

Application executed by the correct applicants.

Please correct this error as soon as possible and charge all the necessary fees to Pennie & Edmonds LLP Deposit Account no. 16-1150. A duplicate of this sheet is enclosed.

Respectfully submitted,

Respectfully submitted,
Authory M. clusogna, My. No. 35, 203

Mystellur E. Luy, Hy. No. 36, 343

Anthony M. Insogna (Reg. No.)

Date: March 15, 2002

PENNIE & EDMONDS LLP

1155 Avenue of the Americas New York, New York 10036-2711 (212) 790-9090




United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
WWW.USTIO.OOV

							www.uspio.gov
APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/910,950 🗸	07/23/2001	1614	0.00	10624-047- 999	·	87	3
20583 PENNIE AND EDMON 1155 AVENUE OF THE NEW YORK, NY 10036	E AMERICAS	Ø	MAR 1 5 200	YO *000	NG RECEI 0000000065788	OT	N NO. 3712 09/19/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer S rvice Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing R ceipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

TRADEMAN



If Required, Foreign Filing License Granted 09/18/2001

· Rachel Ferri, Sun Diego, CA.

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Indazole derivatives as JNK inhibitors and compositions and methods related thereto

Preliminary Class

Data entry by : LEE, KATY	Team : OIPE	Date: 09/19/2001			
· rea(gg) ·					



LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in "or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231